Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 7/20 | 0.50 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14326392 | 0.83 | BRPF1 (0.59) | BRPF1KCNMA1QDPRMAPTSMN1; SMN2 | |
| SCHEMBL28538188 | 0.81 | MAPT (0.49) | ABCB1ABCC1KCNMA1QDPRKMT2A | |
| SCHEMBL4564101 | 0.78 | ABCB1 (0.45) | ABCB1ABCC1KCNMA1KMT2AMEN1 | |
| SCHEMBL522135 | 0.76 | QDPR (0.62) | QDPRLMNA | |
| Hydrochloric Acid SCHEMBL521660 | 0.75 | QDPR (0.61) | QDPRLMNA | |
| Trifluoroacetic Acid SCHEMBL28431227 | 0.73 | QDPR (0.55) | QDPRLMNA | |
| SCHEMBL29803546 | 0.70 | QDPR (0.47) | BRPF1QDPRSMN1; SMN2 | |
| SCHEMBL29803621 | 0.70 | QDPR (0.54) | BRPF1ABCB1ABCC1QDPRKMT2A | |
| SCHEMBL5452132 | 0.70 | RAB9A (0.58) | QDPRKMT2AMEN1LMNAMAPT | |
| SCHEMBL503282 | 0.69 | DHODH (0.72) | ABCB1ABCC1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| EP-2137158-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | MethylGene Inc. (CA) | 2009-12-30 | — | — | EP | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008104077-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | METHYLGENE INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | BRPF1 4004/4885ABCB1 1429/4885ABCC1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.